Risk for hospitalization for heart failure down with SGLT-2i treatment for T2D
For patients with type 2 diabetes (T2D) receiving first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i), the risk for stroke, myocardial infarction (MI), and all-cause mortality is similar to those receiving metformin, ...
May 24, 2022
0
3